• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcturus Therapeutics Holdings Inc (NQ:ARCT)

    20.52 -1.21 (-5.59%)
    Streaming Delayed Price Updated: 11:40 AM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arcturus Therapeutics Holdings Inc

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
    Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
    Via Benzinga
    Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses
    Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying... 
    Via Benzinga
    Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Arcturus Therapeutics
    Via Business Wire
    65 Biggest Movers From Yesterday
    Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of... 
    Via Benzinga
    Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    58 Biggest Movers From Yesterday
    Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
    Via Benzinga
    Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
    Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Gainers Calliditas Therapeutics (NASDAQ:CALT... 
    Via Benzinga
    31 Stocks Moving In Thursday's Mid-Day Session
    Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
    Via Benzinga
    Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Announces Leadership Appointments
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    92 Biggest Movers From Friday
    Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
    Via Benzinga
    Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
    Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal... 
    Via Benzinga
    Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83
    Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level. 
    Via Investor's Business Daily
    Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial
    Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
    Via Benzinga
    Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    Arcturus Therapeutics Earnings Perspective: Return On Capital Employed
    According to Benzinga Pro data, during Q2, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.00 million. Earnings were up 6.84%, but Arcturus Therapeutics still reported an... 
    Via Benzinga
    Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.